Clinical Trial Update: Study of Duvelisib in Combination With Rituximab vs Rituximab in Subjects With Previously Treated Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial of duvelisib plus rituximab versus rituximab alone in previously treated follicular lymphoma was terminated, with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)
• Rituximab (rituximab)

Snippet

Sponsor: SecuraBio | Conditions: Follicular Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2019-01-03